Monica Chen
@monicachenmd
Medical oncology doctor at Memorial Sloan Kettering Cancer Center. Interested in melanoma and early drug development
ID: 1552872482922799106
29-07-2022 04:24:19
27 Tweet
234 Followers
282 Following
Discussion of CNS progression in #EGFR NSCLC by Dr. Monica Chen and ongoing study of amivantamab and lazertinib at #EGFRSummit2022 EGFR Resisters #LCSM #LCAM
First conference talk in the books in front of an all star panel of current and future lung cancer superstars ✅ Helena Yu Stephen V Liu, MD Zosia Piotrowska Mary Jo Fidler Lecia Sequist, MD, MPH Chetan Vakkalagadda, MD Jill Feldman Ivy Elkins Joshua Sabari, MD @esinghimd
Repping Team Thoracic at our 1st cycle for survival Rohit Thummalapalli Cycle for Survival MSK Department of Medicine
The exceptional Yonina Murciano-Goroff MSK Department of Medicine Memorial Sloan Kettering Cancer Center presenting @ #AACR23 on combo KRAS G12C inhib LY3537982 w/ pembro seeing a 78% RR in KRAS G12C mut NSCLC!
Honored to receive a 2023 Conquer Cancer Young Investigator Grant to investigate novel targeted therapies for squamous cell lung cancer. Grateful to have incredible mentors and an amazing patient advocate. Congrats to all the awardees! Memorial Sloan Kettering Cancer Center Jill Feldman #ASCO2023
Super star ⭐️ crew of future thoracic oncologists at the ASCO YIA reception! Arielle Elkrief, MD FRCPC Yonit Lavin Rohit Thummalapalli Jane Sui Memorial Sloan Kettering Cancer Center ASCO
Great collaborative effort with Gʀᴇɢᴏʀʏ Rɪᴇʟʏ Noura Choudhury, MD and Sai-Hong Ignatius Ou Kathryn F. Mileham, MD, FACP, FASCO Suresh S. Ramalingam, MD, FASCO groups. Our results suggest there should be less incentive to continue full-dose lorlatinib if toxicities are encountered. JTO & JTO CRR
Lifileucel (TIL cell therapy from Iovance Biotherapeutics) is now FDA approved for advanced PD-1 refractory melanoma!!! The melanoma community is so grateful to the patients, caregivers, and clinicians who have made the clinical trials of this therapy possible and got lifileucel to approval.
Great to present today at the IASLC #TTLC24 meeting on a huge team effort to find better treatments for patients with metastatic EGFR/TP53/RB1 lung cancer in the city I grew up in. Memorial Sloan Kettering Cancer Center EGFR Resisters Helena Yu
The registrational enabling Spearhead-1 study shows that afami-cel, an engineered T cell targeting MAGEA4, has promising efficacy in synovial sarcoma and MRCLS paving the way for T cell therapy in solid tumors. Memorial Sloan Kettering Cancer Center MSK Department of Medicine Sarcoma Service at Memorial Sloan Kettering sciencedirect.com/science/articl…
Today at #AACR24, Yonina Murciano-Goroff will chair a session on novel approaches for targeted therapies. Fellows Monica Chen & Antoine Desilets, MD, MSc will also present. Not to be missed! Memorial Sloan Kettering Cancer Center 2:30 p.m. PT | Ballroom 6 A - Upper Level - Convention Center buff.ly/43OXQJ7
Great way to end @aacr presenting our experience using MSK-IMPACT for HLA genotyping alongside rockstar fellow Antoine Desilets, MD, MSc at a session chaired by our amazing mentor Yonina Murciano-Goroff! Memorial Sloan Kettering Cancer Center #AACR24
What a great #ASCO24 Lung Cancer poster walk. Thanks to Drs. Corey Langer Mihaela Aldea Monica Chen Enriqueta Felip for walking though their posters and all the tips and career advice!
Immensely grateful to AIM at Melanoma Foundation for the opportunity to attend my first Women in Melanoma meeting and connect with such passionate peers and women heroes. Thank you Sam for organizing such an incredible event! #WIM